

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zai Lab Limited
再鼎醫藥有限公司*

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9688)

Notice of Audit Committee Action

The board of directors (the “**Board**”) of Zai Lab Limited (the “**Company**”) hereby announces that the Audit Committee of the Board will, on August 25, 2025 (Monday, U.S. Eastern Time)/August 26, 2025 (Tuesday, Hong Kong Time), consider and approve, among other matters, the unaudited condensed consolidated results of the Company and its subsidiaries for the six months ended June 30, 2025 (the “**Interim Results**”) and its publication in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**HK Listing Rules**”). The Company previously announced the unaudited condensed consolidated results of the Company and its subsidiaries for the three and six months ended June 30, 2025 (the “**Results**”) and filed its quarterly report on Form 10-Q for the quarter ended June 30, 2025 with the U.S. Securities and Exchange Commission (the “**SEC**”) on August 7, 2025.

The Interim Results to be published by the Company in accordance with the HK Listing Rules are the same as the Results previously announced by the Company and filed with the SEC, except for certain additional information required to be disclosed under the HK Listing Rules, together with a reconciliation of the Company’s Results from U.S. Generally Accepted Accounting Principles to International Financial Reporting Standards.

By order of the Board
Zai Lab Limited
Samantha Du
Director, Chairperson and Chief Executive Officer

Hong Kong, August 13, 2025

As at the date of this announcement, the board of directors of the Company comprises Dr. Samantha Du as a director, and Dr. John Diekman, Dr. Richard Gaynor, Ms. Nisa Leung, Mr. William Lis, Mr. Scott W. Morrison, Mr. Leon O. Moulder, Jr., Mr. Michel Vounatsos and Mr. Peter Wirth as independent directors.

** For identification only*